The AABB recommendations for the Choosing Wisely campaign of the American Board of Internal Medicine

Transfusion

Volumn 54, Issue 9, 2014, Pages 2344-2352

  Callum, Jeannie L ^a   Waters, Jonathan H ^a   Shaz, Beth H ^a   Sloan, Steven R ^a   Murphy, Michael F ^a  

^a AABB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; ASCORBIC ACID; FERROUS SULFATE; HEMOGLOBIN; IRON; PROTHROMBIN COMPLEX; RHESUS D ANTIBODY; TRANEXAMIC ACID; VITAMIN K GROUP; WARFARIN; BLOOD GROUP ABO SYSTEM;

ANTICOAGULANT THERAPY; BLEEDING; BLOOD; BLOOD CELL COUNT; BLOOD GROUP; BLOOD GROUP O; BLOOD TRANSFUSION; CLINICAL DECISION MAKING; DRUG EFFICACY; EMERGENCY SURGERY; EPISTAXIS; ERYTHROCYTE TRANSFUSION; HEALTH CARE ORGANIZATION; HEMATOCRIT; HEMODYNAMIC PARAMETERS; HEMOGLOBIN BLOOD LEVEL; HOSPITAL PATIENT; HUMAN; INTERNAL MEDICINE; INTERNATIONAL NORMALIZED RATIO; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON THERAPY; NOTE; OVERALL SURVIVAL; PATIENT CARE; PHYSICIAN; POSTOPERATIVE HEMORRHAGE; PRACTICE GUIDELINE; PREGNANCY; SURGICAL TECHNIQUE; THERAPY; TRANSFUSION MEDICINE; TREATMENT CONTRAINDICATION; BLOOD GROUP ABO SYSTEM; MEDICAL SOCIETY; STANDARDS; UNITED STATES;

ABO BLOOD-GROUP SYSTEM; BLOOD TRANSFUSION; ERYTHROCYTE TRANSFUSION; HUMANS; SOCIETIES, MEDICAL; UNITED STATES; WARFARIN;

EID: 84908202725     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12802     Document Type: Note

References (81)

1. Pfunter AW, Stocks C. Most frequent procedures performed in US hospitals, 2010. [cited 2014 Jul 10]. Available from: http://hcup-us.ahrq.gov/reports/statbriefs/sb149.pdf
2. US Department of Health and Human Services. The 2011 national blood collection and utilization report. 2012. Washington, DC: Department of Health and Human Services.
3. United States Food and Drug Administration. Fatalities reported to FDA following blood collection and transfusion: annual summary for fiscal year 2013. 2014. [cited 2014 Jul 10]. Available from: http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/TransfusionDonationFatalities/ucm391574.htm
4. Hutton B, Fergusson D, Tinmouth A, et al. Transfusion rates vary significantly amongst Canadian medical centres. Can J Anaesth 2005;52:581-90.
5. Bennett-Guerrero E, Zhao Y, O'Brien SM, et al. Variation in use of blood transfusion in coronary artery bypass graft surgery. JAMA 2010;304:1568-75.
6. Frank SM, Savage WJ, Rothschild JA, et al. Variability in blood and blood component utilization as assessed by an anesthesia information management system. Anesthesiology 2012;117:99-106.
7. NHS Blood & Transplant/Royal College of Physicians. National comparative audit of blood transfusion. [cited 2014 Jul 10]. Available from: http://hospital.blood.co.uk/ safe-use/clinical-audit/National-Comparative/index.asp
8. Carson JL, Grossman BJ, Kleinman S, et al. Red blood cell transfusion: a clinical practice guideline from the AABB∗. Ann Intern Med 2012;157:49-58.
9. Qaseem A, Humphrey LL, Fitterman N, et al. Treatment of anemia in patients with heart disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2013;159:770-9.
10. Goodnough LT, Levy JH, Murphy MF. Concepts of blood transfusion in adults. Lancet 2013;381:1845-54.
11. Carson JL, Carless PA, Hebert PC. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev 2012;(4): CD002042.
12. Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013;368:11-21.
13. Salpeter SR, Buckley JS, Chatterjee S. Impact of more restrictive blood transfusion strategies on clinical outcomes: a meta-analysis and systematic review. Am J Med 2014;127:124-31 e3.
14. Rohde JM, Dimcheff DE, Blumberg N, et al. Health careassociated infection after red blood cell transfusion: a systematic review and meta-analysis. JAMA 2014;311:1317-26.
15. Carson JL, Hebert PC. Should we universally adopt a restrictive approach to blood transfusion? It's all about the number. Am J Med 2014;127:103-4.
16. Berger MD, Gerber B, Arn K, et al. Significant reduction of red blood cell transfusion requirements by changing from a double-unit to a single-unit transfusion policy in patients receiving intensive chemotherapy or stem cell transplantation. Haematologica 2012;97:116-22.
17. Leahy MF, Roberts H, Mukhtar SA, et al. A pragmatic approach to embedding patient blood management in a tertiary hospital. Transfusion 2014;54:1133-45.
18. Ma M, Eckert K, Ralley F, et al. A retrospective study evaluating single-unit red blood cell transfusions in reducing allogeneic blood exposure. Transfus Med 2005;15:307-12.
19. Yerrabothala S, Desrosiers KP, Szczepiorkowski ZM, et al. Significant reduction in red blood cell transfusions in a general hospital after successful implementation of a restrictive transfusion policy supported by prospective computerized order auditing. Transfusion 2014. doi: 10.1111/trf.12627.
20. Yazer MH, Triulzi DJ, Reddy V, et al. Effectiveness of a realtime clinical decision support system for computerized physician order entry of plasma orders. Transfusion 2013; 53:3120-7.
21. Collins RA, Triulzi DJ, Waters JH, et al. Evaluation of realtime clinical decision support systems for platelet and cryoprecipitate orders. Am J Clin Pathol 2014;141:78-84.
22. Frank SM, Resar LM, Rothschild JA, et al. A novel method of data analysis for utilization of red blood cell transfusion. Transfusion 2013;53:3052-9.
23. Cohn CS, Welbig J, Bowman R, et al. A data-driven approach to patient blood management. Transfusion 2014; 54:316-22.
24. Center for Disease Control and Prevention. Recommendations to prevent and control iron deficiency in the United States. MMWR Recomm Repo 1998;47:1-29.
25. Cooper M, Greene-Finestone L, Lowell H, et al. Iron sufficiency of Canadians. Health Rep 2012;23:41-8.
26. Friedman AJ, Chen Z, Ford P, et al. Iron deficiency anemia in women across the life span. JWomens Health 2012;21: 1282-9.
27. Rockey DC, Cello JP. Evaluation of the gastrointestinal tract in patients with iron-deficiency anemia. N Engl J Med 1993;329:1691-5.
28. Zlotkin SH, Ste-Marie M, Kopelman H, et al. The prevalence of iron depletion and iron-deficiency anemia in a randomly selected group of infants from four Canadian cities. Nutr Res 1996;16:729-33.
29. Centers for Disease Control and Prevention (CDC). Iron deficiency-United States, 1999-2000. MMWR Morb Mortal Wkly Rep 2002;51:897-9.
30. Pusic MV, Dawyduk BJ, Mitchell D. Opportunistic screening for iron-deficiency in 6-36 month old children presenting to the paediatric emergency department. BMC Pediatr 2005;5:42.
31. Mekky M, Jasuja M, Parkin PC. Moderate and severe microcytic anemia in the emergency department: indicators of care. Clin Pediatr 2009;48:902-3.
32. Saxena S, Rabinowitz AP, Johnson C, et al. Iron-deficiency anemia: a medically treatable chronic anemia as a model for transfusion overuse. Am J Med 1993;94:120-4.
33. Rohrig G, Klossok W, Becker I, et al. Prevalence of anemia among elderly patients in an emergency room setting. Eur Geriatri Med 2014;5:3-7.
34. Grey DE, Finlayson J. Red cell transfusion for irondeficiency anaemia: a retrospective audit at a tertiary hospital. Vox Sang 2008;94:138-42.
35. Bjarnason I. Gastrointestinal safety of NSAIDs and overthe-counter analgesics. Int J Clin Pract Suppl 2013;(178): 37-42.
36. Murphy MF, Wallington TB, Kelsey P, et al. Guidelines for the clinical use of red cell transfusions. Br J Haematol 2001;113:24-31.
37. Shander A, Hofmann A, Ozawa S, et al. Activity-based costs of blood transfusions in surgical patients at four hospitals. Transfusion 2010;50:753-65.
38. Society for the Advancement of Blood Management. Iron corner. A physician's guide to oral iron supplements. November 2013. [cited 2014 Jul 10]. Available from: http:// iron.sabm.org/overview/treatment.php
39. Lee GR. Iron deficiency and iron-deficiency anaemia. In: Lee GR, Foerster J, Lukens J, editors. Wintrobe's clinical hematology. Vol. 10. 10th ed. Baltimore (MD): Williams & Wilkins; 1999. p. 979-1011.
40. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003;139:893-900.
41. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e419S-94S.
42. Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation 2013;128:1234-43.
43. Tinmouth A, Thompson T, Arnold DM, et al. Utilization of frozen plasma in Ontario: a provincewide audit reveals a high rate of inappropriate transfusions. Transfusion 2013; 53:2222-9.
44. Sarode R, Refaai MA, Matevosyan K, et al. Prospective monitoring of plasma and platelet transfusions in a large teaching hospital results in significant cost reduction. Transfusion 2010;50:487-92.
45. van der Meer FJ, Rosendaal FR, Vandenbroucke JP, et al. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 1993;153:1557-62.
46. Hylek EM, Chang YC, Skates SJ, et al. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med 2000;160: 1612-7.
47. Garcia DA, Regan S, Crowther M, et al. The risk of hemorrhage among patients with warfarin-associated coagulopathy. J Am Coll Cardiol 2006;47:804-8.
48. Tran HA, Chunilal SD, Harper PL, et al. An update of consensus guidelines for warfarin reversal. Med J Aust 2013; 198:198-9.
49. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e152S-84S.
50. Keeling D, Baglin T, Tait C, et al. Guidelines on oral anticoagulation with warfarin-fourth edition. Br J Haematol 2011;154:311-24.
51. Watson HG, Baglin T, Laidlaw SL, et al. A comparison of the efficacy and rate of response to oral and intravenous vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol 2001;115:145-9.
52. Lubetsky A, Yonath H, Olchovsky D, et al. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med 2003;163:2469-73.
53. Meehan R, Tavares M, Sweeney J. Clinical experience with oral versus intravenous vitamin K for warfarin reversal. Transfusion 2013;53:491-8; quiz 0.
54. Toth P, van Veen JJ, Robinson K, et al. Real world usage of PCC to "rapidly" correct warfarin induced coagulopathy. Blood Transfus 2013;11:500-5.
55. Shah N, Sarode R. Warfarin reversal: schism between clinical practice and published guidelines. Transfusion 2013;53: 476-9.
56. Tazarourte K, Riou B, Tremey B, et al. Guidelineconcordant administration of prothrombin complex concentrate and vitamin K is associated with decreased mortality in patients with severe bleeding under vitamin K antagonist treatment (EPAHK study). Critical Care 2014;18: R81.
57. Fiore LD, Scola MA, Cantillon CE, et al. Anaphylactoid reactions to vitamin K. J Thromb Thrombolysis 2001;11: 175-83.
58. Thavendiranathan P, Bagai A, Ebidia A, et al. Do blood tests cause anemia in hospitalized patients? The effect of diagnostic phlebotomy on hemoglobin and hematocrit levels. J Gen Intern Med 2005;20:520-4.
59. Salisbury AC, Reid KJ, Alexander KP, et al. Diagnostic blood loss from phlebotomy and hospital-acquired anemia during acute myocardial infarction. Arch Intern Med 2011; 171:1646-53.
60. Neilson EG, Johnson KB, Rosenbloom ST, et al. The impact of peer management on test-ordering behavior. Ann Intern Med 2004;141:196-204.
61. Attali M, Barel Y, Somin M, et al. A cost-effective method for reducing the volume of laboratory tests in a universityassociated teaching hospital. Mt Sinai J Med 2006;73:787-94.
62. Stuebing EA, Miner TJ. Surgical vampires and rising health care expenditure: reducing the cost of daily phlebotomy. Arch Surg 2011;146:524-7.
63. Wandt H, Schaefer-Eckart K, Wendelin K, et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet 2012; 380:1309-16.
64. Slichter SJ, Davis K, Enright H, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005;105:4106-14.
65. Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010;362:600-13.
66. Sennels HP, Jorgensen HL, Hansen AL, et al. Diurnal variation of hematology parameters in healthy young males: the Bispebjerg study of diurnal variations. Scand J Clin Lab Invest 2011;71:532-41.
67. Shaz, BH, Hillyer CD, Roshal M, et al., editors. Transfusion medicine and hemostasis: clinical and laboratory aspects. 2nd ed. San Diego (CA): Elsevier; 2013.
68. Murphy EL, Shaz B, Hillyer CD, et al. Minority and foreignborn representation among US blood donors: demographics and donation frequency for 2006. Transfusion 2009;49: 2221-8.
69. Pham HP, Shaz BH. Update on massive transfusion. Br J Anaesth 2013;111:i71-i82.
70. Bhella S, Gerard L, Lin Y, et al. Obstetric and trauma database review at a single institution finds the optimal maternal age restriction for the transfusion of O-blood to women involved in trauma to be 45 years. Transfusion 2012;52:2488-9.
71. Yazer MH, Triulzi DJ. Detection of anti-D in D-recipients transfused with D+ red blood cells. Transfusion 2007;47: 2197-201.
72. Cid J, Carbasse G, Pereira A, et al. Platelet transfusions from D+ donors to D-patients: a 10-year follow-up study of 1014 patients. Transfusion 2011;51:1163-9.
73. Molnar R, Johnson R, Sweat LT, et al. Absence of D alloimmunization in D-pediatric oncology patients receiving D-incompatible single-donor platelets. Transfusion 2002;42:177-82.
74. Ayache S, Herman JH. Prevention of D sensitization after mismatched transfusion of blood components: toward optimal use of RhIG. Transfusion 2008;48: 1990-9.
75. National Blood Transfusion Committee. The appropriate use of group O RhD negative red cells. April 2009. [cited 2014 Jul 10]. Available from: http://hospital.blood.co.uk/ library/pdf/nbtc-bbt-o-neg-red-cells-recs-09-04.pdf
76. Gonzalez-Porras JR, Graciani IF, Perez-Simon JA, et al. Prospective evaluation of a transfusion policy of D+ red blood cells into D- patients. Transfusion 2008;48: 1318-24.
77. Yuan S, Davis R, Lu Q, et al. Low risk of alloimmunization to the D antigen in D- orthotopic liver transplant recipients receiving D+ RBCs perioperatively. Transfusion 2008; 48:2653-5.
78. Ramsey G, Hahn LF, Cornell FW, et al. Low rate of Rhesus immunization from Rh-incompatible blood transfusions during liver and heart transplant surgery. Transplantation 1989;47:993-5.
79. Boctor FN, Ali NM, Mohandas K, et al. Absence of D-alloimmunization in AIDS patients receiving D-mismatched RBCs. Transfusion 2003;43: 173-6.
80. Dutton RP, Shih D, Edelman BB, et al. Safety of uncrossmatched type-O red cells for resuscitation from hemorrhagic shock. J Trauma 2005;59:1445-9.
81. Goodell PP, Uhl L, Mohammed M, et al. Risk of hemolytic transfusion reactions following emergency-release RBC transfusion. Am J Clin Pathol 2010;134:202-6.